Advertisement
Advertisement
U.S. markets open in 35 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Liminal BioSciences Inc. (LMNL)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
8.500.00 (0.00%)
At close: 03:59PM EDT
Advertisement

Liminal BioSciences Inc.

440 Armand-Frappier Boulevard
Suite 300
Laval, QC H7V 4B4
Canada
450 781 0115
https://www.liminalbiosciences.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Bruce Pritchard BA, CA, FIODChief Exec. Officer698.94kN/A1974
Mr. Patrick SartorePres613.82kN/A1975
Dr. Gary J. Bridger Ph.D.Interim Chief Scientific Officer & Non-Independent Director264.69kN/A1963
Ms. Marie Iskra L.L.B.Corp. Sec. & Gen. Counsel435.82kN/A1977
Ms. N. Nicole Rusaw C.A., C.P.A., CA, CPA, HBACCChief Financial OfficerN/AN/A1973
Shrinal InamdarMang. of Investor Relations & CommunicationsN/AN/AN/A
Dr. Steven J. BurtonPres of Prometic Bioseparations LtdN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Liminal BioSciences Inc., a development stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company is developing LMNL6511, a selective antagonist for the G-protein coupled receptor 84, is expected to commence a Phase 1 clinical trial. It is also developing potential OXER1 antagonists and GPR40 agonists, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.

Corporate Governance

Liminal BioSciences Inc.’s ISS Governance QualityScore as of September 1, 2023 is 8. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement